Capricor Therapeutics Inc Q4 2017 Big Money Sentiment Better Than Expected, now at 4.33

May 16, 2018 - By Richard Doty

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Corporate Logo

Positions for Capricor Therapeutics Inc (NASDAQ:CAPR)

In Q4 2017 Capricor Therapeutics Inc (NASDAQ:CAPR) big money sentiment increased to 4.33, filings reveal. So its up 2.53, from 2017Q3’s 1.8. 13 investment professionals started new or increased equity positions, while 3 reduced and sold holdings in Capricor Therapeutics Inc so the sentiment improved. These funds own 4.44 million shares, that’s up from 735,965 shares in 2017Q3. Funds holding Capricor Therapeutics Inc in top 10 changed to 0 from 0 for the same number . 3 Investors Sold All; 0 Reduced Holdings; 6 increased holdings while 7 investment professionals bought holdings.

Most Capricor Therapeutics Inc Investors

As of Q4 2017 Apriem Advisors has 0.02% invested in Capricor Therapeutics Inc. Capricor Therapeutics Inc’s shareholder Brown Advisory Inc owns 1.14 million shares as of Q4 2017. Cordasco Financial Network reported 3,100 shares. The Massachusetts-based fund Granite Point Capital Management L.P. have invested about 0.01% of the fund’s stock portfolio in Capricor Therapeutics Inc. The Massachusetts-based fund Acadian Asset Management Llc holds 47,489 shares or 0% of their US long equity exposure.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases.The firm is valued at $37.72 million. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions.14.56 is the P/E ratio.

The stock increased 0.77% or $0.01 during the last trading session, hitting $1.31.Capricor Therapeutics, Inc. has volume of 121,337 shares. Since May 16, 2017 CAPR has declined 60.12% and is downtrending. The stock underperformed the S&P500 by 71.67%.

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s quarterly earnings will be published on August, 9., according to RTT. Analysts predict $-0.11 earnings per share. That’s $0.05 up or 31.25 % from 2017’s earnings of $-0.16. Wall Street predicts -21.43 % EPS growth as of August, 9.

5,616 were reported by Blackrock. 38,660 were accumulated by Northern. Apriem Advsr owns 50,000 shs. Moreover, Geode Capital Mgmt Lc has 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 76,996 shs. Perceptive Advisors Ltd Company reported 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Vanguard Grp Incorporated stated it has 0% of its capital in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Granite Point Limited Partnership owns 33,750 shs. Bank & Trust Of America Corporation De holds 0% or 6,500 shs. Financial Bank Of New York Mellon reported 27,442 shs or 0% of all its holdings. Acadian Asset Mgmt Ltd Llc holds 47,489 shs. Cordasco holds 3,100 shs or 0.01% of its capital. 35,300 were reported by Wells Fargo & Company Mn. Citadel Advsrs Ltd Liability Com has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Royal Bank Of Canada holds 232 shs. Financial Architects holds 0% of its capital in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 2,000 shs.

For more Capricor Therapeutics, Inc. (NASDAQ:CAPR) news released recently go to:,,, or The titles are as follows: “Benzinga’s Top Upgrades, Downgrades For May 16, 2018” released on May 16, 2018, “Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10” on May 04, 2018, “Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy” with a publish date: April 30, 2018, “Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal” and the last “Capricor Therapeutics’ (CAPR) CEO Linda Marbán on Q1 2018 Results – Earnings Call Transcript” with publication date: May 10, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.